ArticleJPGN reports2026
When manual disimpaction isn't enough: Case report and review of neostigmine's role in refractory constipation management.
Article in JPGN reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe refractory constipation can lead to fecal retention requiring hospitalization, nasogastric cleanout, or manual disimpaction, and in some cases, surgery. Neostigmine, a reversible acetylcholinesterase inhibitor, is commonly used for pseudo-obstruction but rarely for refractory constipation. Here, we report a 21-year-old male with chronic constipation and likely undiagnosed autism spectrum disorder hospitalized for severe fecal retention, unresponsive to nasogastric polyethylene glycol. Manual disimpaction removed distal stool but left significant proximal stool burden. A carefully monitored trial of intravenous neostigmine, 4 mg in divided doses, resulted in substantial stool passage without bradycardia or other adverse effects. This case highlights neostigmine as a safe and effective adjunct to manual disimpaction. Its use may improve outcomes and reduce the need for surgical intervention in select patients with complex gastrointestinal motility disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.